Effect of recombinant human interleukin 2 in experimental murine coccidioidomycosis.
The therapeutic effect of recombinant human interleukin 2 (rH IL-2) was assessed in experimental murine coccidioidomycosis by daily IV injection for 30 days of doses ranging decimally from 2.5 X 10(1) to 2.5 X 10(5) units. The treatment with rH IL-2 had neither adverse nor salutary effects.
Hoeprich
P D
PD
Department of Internal Medicine, School of Medicine, University of California, Davis, Medical Center, Sacramento 95817.
Merry
J M
JM
D000666:Amphotericin B / Q000494:pharmacology; D000818:Animals; D003047:Coccidioidomycosis / Q000628:therapy*; D005260:Female; D007376:Interleukin-2 / Q000494:pharmacology / Q000627:therapeutic use*; D008099:Liver / Q000382:microbiology; D008168:Lung / Q000382:microbiology; D051379:Mice; D011994:Recombinant Proteins / Q000494:pharmacology / Q000627:therapeutic use; D013154:Spleen / Q000382:microbiology
D007376:Interleukin-2; D011994:Recombinant Proteins; D000666:Amphotericin B